The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas
Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT) with F-18 fluorodeoxyglucose (18F-FDG) for monitoring the effectiveness and prognosis of lymphoma therapy.Materials and methods. Retrospective data of 18F-FDG PET/CT (before treatment (PET1), after...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2021-07-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/4388 |
| _version_ | 1827991419273347072 |
|---|---|
| author | N. G. Chanchikova V. I. Chernov E. A. Dudnikova E. A. Karlova A. S. Savelyeva O. A. Silkina R. V. Zelchan O. D. Bragin A. A. Medvedeva E. V. Berezneeva |
| author_facet | N. G. Chanchikova V. I. Chernov E. A. Dudnikova E. A. Karlova A. S. Savelyeva O. A. Silkina R. V. Zelchan O. D. Bragin A. A. Medvedeva E. V. Berezneeva |
| author_sort | N. G. Chanchikova |
| collection | DOAJ |
| description | Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT) with F-18 fluorodeoxyglucose (18F-FDG) for monitoring the effectiveness and prognosis of lymphoma therapy.Materials and methods. Retrospective data of 18F-FDG PET/CT (before treatment (PET1), after two cycles (PET2), and after completion of chemotherapy (PET3)) in 30 people with lymphomas were analyzed.Results. A complete metabolic response in PET2 (PET2–) was observed in 21 patients (70%). In 9 patients in PET2–, a partial metabolic response (6 people), lack of metabolic response (2 people), or metabolic progression (1person) were detected. These patients comprised the PET2+ group.After chemotherapy, a complete metabolic response (PET3–) was diagnosed in 26 patients (87%). This effect was achieved in 21 patients (100%) with PET2– and in 5 patients (66%) with PET2+. Of the 9 patients in the PET2+ group, in 4 (44%) patients, a partial metabolic response or no metabolic response was diagnosed. Further monitoring of these patients showed that progression was diagnosed in 2 cases, and in 2 patients, further treatment resulted in complete remission. A two-year follow-up of patients revealed that remission was observed in 20 (67%) patients. The analysis of the results of PET2 showed that a relapse of the disease was observed in 6 (67%) PET2+ patients and remission was noted in 3 (33%) patients. In PET2– patients, a relapse was diagnosed in 4 (19%) persons, and remission was established in 17 (81%) patients.Conclusion. Early PET/CT with 18F-FDG allows to predict the effect of lymphoma treatment. The method can be recommended for monitoring lymphoma therapy. |
| first_indexed | 2024-04-10T01:04:54Z |
| format | Article |
| id | doaj.art-0d58b28fba034a09976c827f2a801424 |
| institution | Directory Open Access Journal |
| issn | 1682-0363 1819-3684 |
| language | English |
| last_indexed | 2024-04-10T01:04:54Z |
| publishDate | 2021-07-01 |
| publisher | Siberian State Medical University (Tomsk) |
| record_format | Article |
| series | Бюллетень сибирской медицины |
| spelling | doaj.art-0d58b28fba034a09976c827f2a8014242023-03-13T09:58:27ZengSiberian State Medical University (Tomsk)Бюллетень сибирской медицины1682-03631819-36842021-07-0120212012910.20538/1682-0363-2021-2-120-1292789The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomasN. G. Chanchikova0V. I. Chernov1E. A. Dudnikova2E. A. Karlova3A. S. Savelyeva4O. A. Silkina5R. V. Zelchan6O. D. Bragin7A. A. Medvedeva8E. V. Berezneeva9Федеральный Сибирский научно-клинический центр Федерального медико-биологического агентства (ФСНКЦ ФМБА)Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук; Национальный исследовательский Томский политехнический университет (НИ ТПУ)Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукФедеральный Сибирский научно-клинический центр Федерального медико-биологического агентства (ФСНКЦ ФМБА)Федеральный Сибирский научно-клинический центр Федерального медико-биологического агентства (ФСНКЦ ФМБА)Федеральный Сибирский научно-клинический центр Федерального медико-биологического агентства (ФСНКЦ ФМБА)Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук; Национальный исследовательский Томский политехнический университет (НИ ТПУ)Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук; Национальный исследовательский Томский политехнический университет (НИ ТПУ)Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наукНациональный исследовательский Томский политехнический университет (НИ ТПУ)Aim. To determine the diagnostic value of positron emission tomography (PET)/computed tomography (CT) with F-18 fluorodeoxyglucose (18F-FDG) for monitoring the effectiveness and prognosis of lymphoma therapy.Materials and methods. Retrospective data of 18F-FDG PET/CT (before treatment (PET1), after two cycles (PET2), and after completion of chemotherapy (PET3)) in 30 people with lymphomas were analyzed.Results. A complete metabolic response in PET2 (PET2–) was observed in 21 patients (70%). In 9 patients in PET2–, a partial metabolic response (6 people), lack of metabolic response (2 people), or metabolic progression (1person) were detected. These patients comprised the PET2+ group.After chemotherapy, a complete metabolic response (PET3–) was diagnosed in 26 patients (87%). This effect was achieved in 21 patients (100%) with PET2– and in 5 patients (66%) with PET2+. Of the 9 patients in the PET2+ group, in 4 (44%) patients, a partial metabolic response or no metabolic response was diagnosed. Further monitoring of these patients showed that progression was diagnosed in 2 cases, and in 2 patients, further treatment resulted in complete remission. A two-year follow-up of patients revealed that remission was observed in 20 (67%) patients. The analysis of the results of PET2 showed that a relapse of the disease was observed in 6 (67%) PET2+ patients and remission was noted in 3 (33%) patients. In PET2– patients, a relapse was diagnosed in 4 (19%) persons, and remission was established in 17 (81%) patients.Conclusion. Early PET/CT with 18F-FDG allows to predict the effect of lymphoma treatment. The method can be recommended for monitoring lymphoma therapy.https://bulletin.ssmu.ru/jour/article/view/4388лимфома ходжкинанеходжкинские лимфомыкомпьютерная томографияпозитронная эмиссионная томографиямониторинг терапии лимфомпрогноз терапии лимфом |
| spellingShingle | N. G. Chanchikova V. I. Chernov E. A. Dudnikova E. A. Karlova A. S. Savelyeva O. A. Silkina R. V. Zelchan O. D. Bragin A. A. Medvedeva E. V. Berezneeva The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas Бюллетень сибирской медицины лимфома ходжкина неходжкинские лимфомы компьютерная томография позитронная эмиссионная томография мониторинг терапии лимфом прогноз терапии лимфом |
| title | The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas |
| title_full | The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas |
| title_fullStr | The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas |
| title_full_unstemmed | The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas |
| title_short | The role of <sup>18</sup>F-FDG PET/CT in evaluation of therapy effectiveness and prognosis of lymphomas |
| title_sort | role of sup 18 sup f fdg pet ct in evaluation of therapy effectiveness and prognosis of lymphomas |
| topic | лимфома ходжкина неходжкинские лимфомы компьютерная томография позитронная эмиссионная томография мониторинг терапии лимфом прогноз терапии лимфом |
| url | https://bulletin.ssmu.ru/jour/article/view/4388 |
| work_keys_str_mv | AT ngchanchikova theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT vichernov theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT eadudnikova theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT eakarlova theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT assavelyeva theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT oasilkina theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT rvzelchan theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT odbragin theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT aamedvedeva theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT evberezneeva theroleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT ngchanchikova roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT vichernov roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT eadudnikova roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT eakarlova roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT assavelyeva roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT oasilkina roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT rvzelchan roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT odbragin roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT aamedvedeva roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas AT evberezneeva roleofsup18supffdgpetctinevaluationoftherapyeffectivenessandprognosisoflymphomas |